Coherus Biosciences Could Be First-To-Market With A Neulasta Biosimilar
October 03, 2016 at 12:57 PM EDT
Barclays maintained its Overweight rating on Coherus Biosciences Inc (NASDAQ: CHRS) saying there is an increased likelihood of CHRS ...